Patients with HAM/TSP without steroid therapy during the observation period (Untreated group, n = 185) | Patients with HAM/TSP with at least once steroid therapy during the observation period (Steroid group, n = 225) | Patients with HAM/TSP who had continued steroid therapy during the observation period (Continued steroid group, n = 181) | |
---|---|---|---|
OMDS 1–4 | 46 (24.9%) | 51 (22.7%) | 39 (21.5%) |
OMDS 5 | 54 (29.2%) | 91 (40.4%) | 71 (39.2%) |
OMDS 6 | 34 (18.4%) | 38 (16.9%) | 34 (18.8%) |
OMDS 7–13 | 51 (27.6%) | 45 (20.0%) | 37 (20.4%) |
Steroid-related complications | Incidence per 1000 person-yearsa | Incidence per 1000 person-yearsa | Incidence per 1000 person-yearsa |
Bone fracture | 48.3 (33.0–70.8) | 61.0 (45.1–82.5) | 65.6 (47.4–90.8) |
OMDS 1–4 | 42.9 (18.3–100.5) | 33.4 (14.2–78.1) | 35.0 (13.6–90.1) |
OMDS 5 | 26.2 (10.2–67.3) | 76.5 (50.0–116.9) | 83.4 (52.8–131.9) |
OMDS 6 | 72.4 (36.7–142.9) | 60.3 (29.2–124.5) | 48.4 (20.7–113.2) |
OMDS 7–13 | 56.8 (29.9–107.9) | 60.9 (32.0–115.7) | 77.9 (41.0–148.0) |
Lower limb fracture | 21.8 (12.5–38.1) | 24.2 (15.1–38.7) | 26.7 (16.2–44.0) |
OMDS 1–4 | 0.0 (0.0–30.5) | 6.6 (1.2–37.6) | 8.7 (1.5–49.2) |
OMDS 5 | 25.8 (10.0–66.4) | 25.1 (12.1–51.7) | c |
OMDS 6 | 35.6 (13.8–91.4) | 8.4 (1.5–47.5) | 0.0 (0.0–36.1) |
OMDS 7–13 | 25.4 (9.9–65.4) | 51.8 (26.3–102.3) | 65.6 (33.2–129.4) |
Compression fracture | 16.1 (8.5–30.6) | 25.4 (16.1–40.2) | 28.1 (17.3–45.7) |
OMDS 1–4 | 8.4 (1.5–47.5) | 13.1 (3.6–47.7) | 17.1 (4.7–62.3) |
OMDS 5 | 0.0 (0.0–24.0) | 28.3 (14.4–55.9) | 26.8 (12.3–58.5) |
OMDS 6 | 35.5 (13.8–91.4) | 42.4 (18.1–99.2) | 47.5 (20.3–111.2) |
OMDS 7–13 | 23.8 (9.3–61.2) | 19.4 (6.6–57.0) | 24.5 (8.3–72.0) |
Herpes Zoster | 8.8 (3.8–20.6) | 12.7 (6.7–24.1) | 12.3 (6.0–25.4) |
Diabetes mellitusb | 9.0 (3.9–21.2) | 4.4 (1.5–13.1) | 5.6 (1.9–16.5) |
Cataractb | 9.2 (3.9–21.5) | 9.1 (4.2–19.8) | 7.5 (2.9–19.4) |
Glaucomab | 3.6 (1.0–13.0) | 1.4 (0.3–8.2) | 1.8 (0.3–10.2) |